Brief: Alx Oncology Presents Positive Updated Data From Aspen-06 Phase 2 Trial
23/01/2025 13:09
Jan 23 (Reuters) - ALX Oncology Holdings Inc ALXO.O :
* ALX ONCOLOGY PRESENTS POSITIVE UPDATED DATA FROM ASPEN-06
PHASE
2 TRIAL DEMONSTRATING EVORPACEPT GENERATES STRONG RESPONSE AND
DURABLE CLINICAL BENEFIT IN PATIENTS WITH HER2-POSITIVE GASTRIC
CANCER
Source text: ID:nGNX9RtQVV
Further company coverage: ALXO.O
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing